טוען...
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...
שמור ב:
| הוצא לאור ב: | Immunotargets Ther |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918241/ https://ncbi.nlm.nih.gov/pubmed/27471705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40264 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|